AS 101

Drug Profile

AS 101

Alternative Names: AS101; CB-06-02; IVAX-Q-101; IVX-Q-101; Ossirene; WAX-120337

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bar-Ilan University
  • Developer BioMAS; Cassiopea
  • Class Antineoplastics; Antipsoriatics; Antivirals; Nitrogen compounds; Organometallic compounds; Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration; Genital warts
  • Preclinical Female infertility; Male infertility
  • Discontinued Acute myeloid leukaemia; Atopic dermatitis; Chemotherapy-induced damage; HIV infections; Myelodysplastic syndromes; Neurological disorders; Psoriasis; Thrombocytopenia

Most Recent Events

  • 07 Dec 2017 BioMAS completes enrolment in its phase II trial for Genital warts in Israel (NCT01943630)
  • 11 Jul 2017 Feramda plans a phase I/II trial for Wet age related macular degeneration (PO, Solution) (NCT03216538)
  • 07 Aug 2015 Phase-II development is ongoing for Genital warts in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top